Phase III clinical trials for the Novavax COVID-19 vaccine candidate conclude in the U.S. and Mexico, showing an efficacy rating of 90.4%
Phase III clinical trials for the Novavax COVID-19 vaccine candidate conclude in the U.S. and Mexico, showing an efficacy rating of 90.4%, down from the initial estimate of 96.4% efficacy reported in March. Additionally, the vaccine candidate was also found to be 86.3% effective against the Lineage B.1.1.7 Alpha variant that originated in the United Kingdom.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
Phase III clinical trials for the Novavax COVID-19 vaccine candidate conclude in the U.S. and Mexico, showing an efficacy rating of 90.4%, down from the initial estimate of 96.4% efficacy reported in March. Additionally, the vaccine candidate was also found to be 86.3% effective against the Lineage B.1.1.7 Alpha variant that originated in the United Kingdom.